Navigation Links
First-of-its-Kind National Report Reveals Estimated High Prevalence,and Heavy Cost of Type 2 Diabetes Complications in America

In Response, Health Organizations Unite to Help Educate on Good Diabetes Management and How to Reduce the Risk of Other Serious Health Problems

SEATTLE, April 10, 2007 /PRNewswire/ -- A first-of-its-kind report looking at the prevalence and cost of type 2 diabetes complications shows that an estimated three out of five people (57.9 percent) with type 2 diabetes have at least one of the other serious health problems commonly associated with the disease, and that these health problems are taking a heavy financial toll on the United States. In 2006, the nation spent an estimated $22.9 billion on direct medical costs related to diabetes complications.*

The new report, titled State of Diabetes Complications in America, also shows that estimated annual healthcare costs for a person with type 2 diabetes complications are about three times higher than that of the average American without diagnosed diabetes. These complications, which can include heart disease, stroke, eye damage, chronic kidney disease and foot problems that can lead to amputations, cost a person with type 2 diabetes almost $10,000 each year.* People with diabetes complications pay nearly $1,600 out of their own pockets for costs that are not reimbursed by insurance, such as co-payments and deductibles.* This amount is significant, considering that according to the National Health Interview Survey, an estimated 40 percent of adults with diabetes reported a family income of less than $35,000 per year in 2005.

Results from the report were released today at the American Association of Clinical Endocrinologists' (AACE) 16th Annual Meeting and Clinical Congress, by AACE in partnership with the members of a diabetes complications consortium: the Amputee Coalition of America, Mended Hearts, the National Federation of the Blind and the National Kidney Foundation, and supported by GlaxoSmithKline.

* Cost estimates in this report were adjust
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
6. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
7. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
8. Advanced Magnetics Announces Presentation of Ferumoxytol Data at the National Kidney Foundation 2007 Spring Clinical Meetings
9. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
10. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:12/2/2008)...if., Dec. 2 TorreyPines Therapeuti...e results from a 26 patient Phase II trial evaluat...tomia, or dry mouth, in patients with Sjogren,s sy...istically significant increase in salivary flow pr...0 mg, 15 mg, and 20 mg. These doses were safe and ...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/2/2008)..., Dec. 2 Micromet, Inc. ...eloping novel, proprietary antibodies for the trea...ses, today announced that it has entered into an a...Facility (CEFF) with Kingsbridge Capital Limited, ...e agreement, Kingsbridge has committed to provide ...
(Date:12/1/2008)... 2 New research has fou... computed tomography (CT) scanner in an emergency ...ke victims who receive a potentially life-saving t... Shore Medical Center (NSMC)-Salem Hospital in Sal...eeting of the Radiological Society of North Americ...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3NCPA Applauds U S House Vote in Favor of H R 6331 22698 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 2New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 3New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 4New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 5New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 6New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 7New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 8New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 9Drug Coated Stents Reduce Repeat Artery Procedures 22693 1Drug Coated Stents Reduce Repeat Artery Procedures 22693 2Drug Coated Stents Reduce Repeat Artery Procedures 22693 3Certain anti cancer agents could be harmful to patients with heart disease 22689 1Certain anti cancer agents could be harmful to patients with heart disease 22689 2Certain anti cancer agents could be harmful to patients with heart disease 22689 3
...ON VALLEY, Pa.--(BUSINESS WIRE)--Apr 12, 2007 - Im...at the American,Association for Cancer Research (A...5 to 18. The Company will feature,Immunicon Pharma...at Kit and the new EasyCount(TM) System at booth 1...opment and clinical,trial testing services to some...
...c found to dramatically reduce the risk of cancer,...estinal stromal,tumors (GIST) , * Patients receivi...c , * Global regulatory submissions planned for us...ollowing surgery to remove,primary tumor , * Glive...ts with,advanced metastatic or inoperable Kit-posi...
Other Medicine Technology:Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:12/2/2008)... Zicam Cold & Flu Companion uses loca...tep ahead of cold and flu. , ...Matrixx Initiatives, Inc., makers of Zicam® Co...® Cold & Flu Companion mobile application ...oid-powered phone. The same mobile application wil...
(Date:12/2/2008)...Call to Action Highlights Need to Reduce Dispariti...nal Efforts , , BETHESDA, Md., Dec. 2 /PRN...s Diseases, (NFID) S.T.O.P. (Share. Teach. Outre...f many of the nation,s leading medical and advocac...to improve adolescent meningococcal vaccination ra...
(Date:12/2/2008)...Dec. 2 MedPro Imaging, a premier p... announced the appointment of three,new ultrasoun... aggressive,expansion. The company also announce...cilities due to substantial growth throughout 2008...e president of Sales and Marketing in,February of...
(Date:12/2/2008)...wellness services available to seniors , , ... Alliance Plan (HAP) is adding acupuncture and chi...Benefit for Medicare Advantage members beginning J...promote wellness encourages Medicare beneficiaries...e putting money back in their wallets. , , ...
Breaking Medicine News(10 mins):Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 2Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...tes in the US are stepping up their efforts to for...ds of mercury emissions.// Throughout the Northe...alth concern. Mercury is a metal that occurs natur...seous form when coal is burned in electrical gener...
...in Rajasthan - is all set to travel to war-hit Leb...ts from the Bhagwan Mahaveer Viklang Sahayta Samit...vitation of the Indian contingent of the UN peacek...SS general secretary S.R. Mehta said. The team w...
...stakes made by medical secretaries in India have b...h hospitals// from being outsourced to India and t...tional Health Service (NHS) have outsourced medica...re considering the option to cut budgetary deficit...
...disease in western Bangladesh's Kushtia district i...ng people// as the number of patients rises everyd... more than 50 people are being treated at the hosp...ents is growing day by day, The Daily Star reporte...
Other Medicine News:Health News:US States Get Ready to Fight Mercury Pollution 2Health News:Jaipur Foot Takes Off for Lebanon 2Health News:Outsourcing of UK Hospital Records to India Opposed 2
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve.
Goldman single hook.
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
The amazingly compact refractor VISUTRON 900+ follows a simple principle: one knob is enough. It offers the user maximal ease, speed, and economics. The quick and silent change of glasses helps the
Medicine Products: